Niche CNS focus Cognitive Research Corporation specializes exclusively in CNS Phase I-III trials, signaling a deep domain expertise that can be leveraged to engage sponsors seeking a high-quality, neuroscience-centric CRO for complex CNS programs.

Secured leadership Leadership additions in 2024-2025 including CEO Tom Zoda and CFO Ryan Shortreed, plus a Chief Commercial Officer appointment, indicate strengthened strategic direction and growth execution capabilities ideal for expanding client acquisition and larger deals.

Growing revenue Current revenue range of 25-50 million with a 51-200 employee base suggests scale to support mid to late-phase CNS programs and potential cross-sell of specialized services to existing biotech and pharma sponsors.

Strategic partnerships Recent collaborations such as with Clerkenwell Health for psychedelic CNS research highlight CRC’s openness to co-development models and international expansion opportunities that can broaden service offerings and geographic reach.

Industry engagement Active conference presence and panel participation at ASCP and Lifesavers Conference signals a visible thought leadership stance; this can be leveraged to generate senior sponsor dialogues and multi-program RFP opportunities.